
Lilly, J&J, Pfizer and Sanofi back Teva fight against IRA drug negotiation program
As a drugmaker depending heavily on sales of both branded and non-branded products, Teva has said that it is uniquely affected by how medicines are selected for the Medicare drug price negotiation program in the Inflation Reduction Act (IRA). Two months …